A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

Nan Soon WongDuke University Medical Center, Durham, North Carolina, USA,

Kellen L. MeadowsDuke University Medical Center, Durham, North Carolina, USA,

Lee S. RosenUniversity of California, Los Angeles, Los Angeles, California, USA,

Alex A. AdjeiMayo Clinic, Rochester, Minnesota, USA,

Scott H. KaufmannMayo Clinic, Rochester, Minnesota, USA,

Michael A. MorseDuke University Medical Center, Durham, North Carolina, USA,

William P. PetrosMary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia, USA,

Yali ZhuMerck & Company, Kenilworth, New Jersey, USA

Paul StatkevichMerck & Company, Kenilworth, New Jersey, USA

David L. CutlerMerck & Company, Kenilworth, New Jersey, USA

Michael L. MeyersMerck & Company, Kenilworth, New Jersey, USA

Herbert I. HurwitzDuke University Medical Center, Durham, North Carolina, USA,Correspondence[email protected]

Your download is now in progress and you may close this window